Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 Pipeline Review, H1 2018
Summary
Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 Hepatitis A virus cellular receptor 2 HAVCR2 is a protein encoded by the HAVCR2 gene. It inhibits Thelper type 1 lymphocyte Th1mediated auto and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of Tcell responses the resulting apoptosis of antigenspecific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6.
Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 6 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Lymphoma, NonSmall Cell Lung Cancer, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Bile Duct Cancer Cholangiocarcinoma, Colon Cancer, Colon Carcinoma, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma and Squamous NonSmall Cell Lung Cancer.
The latest report Hepatitis A Virus Cellular Receptor 2 Pipeline Review, H1 2018, outlays comprehensive information on the Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2
The report reviews Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 targeted therapeutics and enlists all their major and minor projects
The report assesses Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope